Voyager Therapeutics (VYGR)
(Delayed Data from NSDQ)
$3.38 USD
+0.17 (5.30%)
Updated Aug 5, 2025 04:00 PM ET
After-Market: $3.40 +0.02 (0.59%) 7:58 PM ET
3-Hold of 5 3
C Value C Growth C Momentum C VGM
Fundamental Charts
About Market Cap
As of the previous market close, Voyager Therapeutics, Inc. has a market cap of $177.63M, which represents its share price of $3.21 multiplied by its outstanding shares number of 55.34M. As a small-cap company, VYGR's shareholders are generally exposed to more risk than shareholders of mid and large-cap companies.
The company's Market Capitalization is a measurement of company size. It is calculation of the company's share price times the number of outstanding shares. Large market cap companies give stability and are good long-term investments. Small market cap companies can produce faster growth and bigger returns, but their stockholders are exposed to more risk.
VYGR 3.38 +0.17(5.30%)
Will VYGR be a Portfolio Killer in August?
Zacks Investment Research is releasing its prediction for VYGR based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for VYGR
Voyager Therapeutics (VYGR) Reports Q1 Loss, Lags Revenue Estimates
Voyager Therapeutics (VYGR) Reports Q4 Loss, Misses Revenue Estimates
VYGR: What are Zacks experts saying now?
Zacks Private Portfolio Services
CytomX Therapeutics (CTMX) Tops Q4 Earnings and Revenue Estimates
TScan Therapeutics, Inc. (TCRX) Reports Q4 Loss, Lags Revenue Estimates
Day One Biopharmaceuticals, Inc. (DAWN) Reports Q4 Loss, Tops Revenue Estimates
Other News for VYGR
Voyager Adds Fourth Wholly-Owned Alzheimer's Disease Program to Pipeline, Complementing ...
Voyager Therapeutics (VYGR) Enhances Alzheimer's Program with New Initiative | VYGR Stock News
Voyager Therapeutics continues expansion of its AD franchise
Voyager to Present at H.C. Wainwright 6th Annual Neuro Perspectives Hybrid Conference | VYGR ...
Voyager Therapeutics: Navigating AAV Headwinds And A Long Road For VY7523 (Downgrade)